• Something wrong with this record ?

Combination of Memantine and 6-Chlorotacrine as Novel Multi-Target Compound against Alzheimer's Disease

M. Kaniakova, E. Nepovimova, L. Kleteckova, K. Skrenkova, K. Holubova, Z. Chrienova, V. Hepnarova, T. Kucera, T. Kobrlova, K. Vales, J. Korabecny, O. Soukup, M. Horak,

. 2019 ; 16 (9) : 821-833. [pub] -

Language English Country United Arab Emirates

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc20025973

BACKGROUND: Alzheimer's disease (AD) is the most common form of dementia in the elderly. It is characterized as a multi-factorial disorder with a prevalent genetic component. Due to the unknown etiology, current treatment based on acetylcholinesterase (AChE) inhibitors and N-methyl-D-aspartate receptors (NMDAR) antagonist is effective only temporary. It seems that curative treatment will necessarily be complex due to the multifactorial nature of the disease. In this context, the so-called "multi-targeting" approach has been established. OBJECTIVES: The aim of this study was to develop a multi-target-directed ligand (MTDL) combining the support for the cholinergic system by inhibition of AChE and at the same time ameliorating the burden caused by glutamate excitotoxicity mediated by the NMDAR receptors. METHODS: We have applied common approaches of organic chemistry to prepare a hybrid of 6-chlorotacrine and memantine. Then, we investigated its blocking ability towards AChE and NMDRS in vitro, as well as its neuroprotective efficacy in vivo in the model of NMDA-induced lessions. We also studied cytotoxic potential of the compound and predicted the ability to cross the blood-brain barrier. RESULTS: A novel molecule formed by combination of 6-chlorotacrine and memantine proved to be a promising multipotent hybrid capable of blocking the action of AChE as well as NMDARs. The presented hybrid surpassed the AChE inhibitory activity of the parent compound 6-Cl-THA twofold. According to results it has been revealed that our novel hybrid blocks NMDARs in the same manner as memantine, potently inhibits AChE and is predicted to cross the blood-brain barrier via passive diffusion. Finally, the MTDL design strategy was indicated by in vivo results which showed that the novel 6-Cl-THA-memantine hybrid displayed a quantitatively better neuroprotective effect than the parent compound memantine. CONCLUSION: We conclude that the combination of two pharmacophores with a synergistic mechanism of action into a single molecule offers great potential for the treatment of CNS disorders associated with cognitive decline and/or excitotoxicity mediated by NMDARs.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20025973
003      
CZ-PrNML
005      
20221024103429.0
007      
ta
008      
201125s2019 ts f 000 0|eng||
009      
AR
024    7_
$a 10.2174/1567205016666190228122218 $2 doi
035    __
$a (PubMed)30819076
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ts
100    1_
$a Kaniakova, Martina $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic. Institute of Physiology of the Czech Academy of Sciences of the Czech Republic, Videnska 1083, 14220 Prague 4, Czech Republic.
245    10
$a Combination of Memantine and 6-Chlorotacrine as Novel Multi-Target Compound against Alzheimer's Disease / $c M. Kaniakova, E. Nepovimova, L. Kleteckova, K. Skrenkova, K. Holubova, Z. Chrienova, V. Hepnarova, T. Kucera, T. Kobrlova, K. Vales, J. Korabecny, O. Soukup, M. Horak,
520    9_
$a BACKGROUND: Alzheimer's disease (AD) is the most common form of dementia in the elderly. It is characterized as a multi-factorial disorder with a prevalent genetic component. Due to the unknown etiology, current treatment based on acetylcholinesterase (AChE) inhibitors and N-methyl-D-aspartate receptors (NMDAR) antagonist is effective only temporary. It seems that curative treatment will necessarily be complex due to the multifactorial nature of the disease. In this context, the so-called "multi-targeting" approach has been established. OBJECTIVES: The aim of this study was to develop a multi-target-directed ligand (MTDL) combining the support for the cholinergic system by inhibition of AChE and at the same time ameliorating the burden caused by glutamate excitotoxicity mediated by the NMDAR receptors. METHODS: We have applied common approaches of organic chemistry to prepare a hybrid of 6-chlorotacrine and memantine. Then, we investigated its blocking ability towards AChE and NMDRS in vitro, as well as its neuroprotective efficacy in vivo in the model of NMDA-induced lessions. We also studied cytotoxic potential of the compound and predicted the ability to cross the blood-brain barrier. RESULTS: A novel molecule formed by combination of 6-chlorotacrine and memantine proved to be a promising multipotent hybrid capable of blocking the action of AChE as well as NMDARs. The presented hybrid surpassed the AChE inhibitory activity of the parent compound 6-Cl-THA twofold. According to results it has been revealed that our novel hybrid blocks NMDARs in the same manner as memantine, potently inhibits AChE and is predicted to cross the blood-brain barrier via passive diffusion. Finally, the MTDL design strategy was indicated by in vivo results which showed that the novel 6-Cl-THA-memantine hybrid displayed a quantitatively better neuroprotective effect than the parent compound memantine. CONCLUSION: We conclude that the combination of two pharmacophores with a synergistic mechanism of action into a single molecule offers great potential for the treatment of CNS disorders associated with cognitive decline and/or excitotoxicity mediated by NMDARs.
650    _2
$a acetylcholinesterasa $x metabolismus $7 D000110
650    _2
$a Alzheimerova nemoc $x farmakoterapie $x metabolismus $7 D000544
650    _2
$a zvířata $7 D000818
650    _2
$a hematoencefalická bariéra $x účinky léků $x metabolismus $7 D001812
650    _2
$a CHO buňky $7 D016466
650    _2
$a kapilární permeabilita $7 D002199
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a cholinesterasové inhibitory $x chemická syntéza $x farmakologie $7 D002800
650    _2
$a Cricetulus $7 D003412
650    _2
$a kyselina glutamová $x metabolismus $7 D018698
650    _2
$a HEK293 buňky $7 D057809
650    _2
$a lidé $7 D006801
650    _2
$a ligandy $7 D008024
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a memantin $x chemická syntéza $x farmakologie $7 D008559
650    _2
$a simulace molekulového dockingu $7 D062105
650    _2
$a neuroprotektivní látky $x chemická syntéza $x farmakologie $7 D018696
650    _2
$a potkani Wistar $7 D017208
650    _2
$a receptory N-methyl-D-aspartátu $x antagonisté a inhibitory $x metabolismus $7 D016194
650    _2
$a takrin $x analogy a deriváty $x chemická syntéza $x farmakologie $7 D013619
650    _2
$a techniky tkáňových kultur $7 D046509
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Nepovimova, Eugenie $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic.
700    1_
$a Kleteckova, Lenka $u National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic.
700    1_
$a Skrenkova, Kristyna $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic.
700    1_
$a Holubova, Kristina $u National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic.
700    1_
$a Chrienova, Zofia $u Department of Chemistry, Faculty of Science, University of Hradec Kralove, Rokitanskeho 62, 500 03 Hradec Kralove, Czech Republic.
700    1_
$a Hepnarova, Vendula $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, Hradec Kralove 500 05, Czech Republic.
700    1_
$a Kucera, Tomas $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, Hradec Kralove 500 05, Czech Republic.
700    1_
$a Kobrlová, Tereza, $u Department of Toxicology and Military Pharmacy, Faculty of Military Health Sciences, University of Defence, Trebesska 1575, Hradec Kralove 500 05, Czech Republic. Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic. $d 1991- $7 xx0277928
700    1_
$a Vales, Karel $u National Institute of Mental Health, Topolova 748, 250 67 Klecany, Czech Republic.
700    1_
$a Korabecny, Jan $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Soukup, Ondrej $u Biomedical Research Centre, University Hospital Hradec Kralove, Sokolska 581, 500 05 Hradec Kralove, Czech Republic.
700    1_
$a Horak, Martin $u Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 14220 Prague 4, Czech Republic. Institute of Physiology of the Czech Academy of Sciences of the Czech Republic, Videnska 1083, 14220 Prague 4, Czech Republic.
773    0_
$w MED00008816 $t Current Alzheimer research $x 1875-5828 $g Roč. 16, č. 9 (2019), s. 821-833
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30819076 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20201125 $b ABA008
991    __
$a 20221024103428 $b ABA008
999    __
$a ok $b bmc $g 1600118 $s 1116659
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 16 $c 9 $d 821-833 $e - $i 1875-5828 $m Current Alzheimer research $n Curr Alzheimer Res $x MED00008816
LZP    __
$a Pubmed-20201125

Find record

Citation metrics

Archiving options